Rachel Vanwettering
Primary Care · Albuquerque, NMNPI 1548965676
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.2% of the total across 104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,212, 3.7 times the $328 reported in 2023. Among primary care clinicians in NM with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$413
- Johnson & Johnson$249
- Novartis$188
- Incyte Corporation$178
- Lilly USA, LLC$174
- Sanofi-aventis U.S. LLC$80
- plus $703 from 21 others
What the payments were for
- Food & beverage$1,83192%
- Education$1558%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $413 |
| Johnson & Johnson | 5 | $249 |
| Novartis | 8 | $188 |
| Incyte Corporation | 8 | $178 |
| Lilly USA, LLC | 10 | $174 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| AstraZeneca | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 1 | $53 |
| Boehringer Ingelheim | 3 | $53 |
| Exact Sciences | 3 | $47 |
| Pfizer | 2 | $44 |
| Amgen | 2 | $42 |
| Biofrontera Inc. | 2 | $40 |
| Mylan Specialty L.p. | 2 | $39 |
| Nevro Corp. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $30 |
| UCB, Inc. | 1 | $27 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $22 |
| Sanofi | 1 | $21 |
| Lundbeck LLC | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $16 |
| LEO Pharma Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Organon | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,986 in reported general payments places this provider in the 90th percentile of 58 primary care providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 12 | $15,381 |
| JardianceEmpagliflozin | 12 | $12,659 |
| XareltoRivaroxaban | 12 | $6,833 |
| Duloxetine Hcl | 11 | $887 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $824 |
| Rosuvastatin Calcium | 22 | $686 |
| Losartan Potassium | 36 | $648 |
| Montelukast Sodium | 24 | $640 |
| Gabapentin | 21 | $385 |
| Levothyroxine Sodium | 27 | $334 |
| Metoprolol Succinate | 16 | $328 |
| Lisinopril | 29 | $303 |
| Amlodipine Besylate | 32 | $297 |
| Atorvastatin Calcium | 27 | $241 |
| Hydroxyzine Hcl | 11 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $53 | $12,65912 claims |
| Johnson & JohnsonXarelto | $249 | $6,83312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 58 primary care providers in New Mexico.
Other primary care in Albuquerque
- Bianca MezaAlbuquerque$59K
- Melissa PinoAlbuquerque$4K
- Jacqueline MessierAlbuquerque$3K
- Christine MayesAlbuquerque$2K
- Catherine JamesAlbuquerque$2K
- Koryn MichaudAlbuquerque$1K
- Christie DommeAlbuquerque$1K
- Pala Nicole RiveraAlbuquerque$905
- Nena VigilAlbuquerque$595
- Michael BrisonAlbuquerque$546
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.